Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
Trial details
- Registry ID
- NCT05643534
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 YearsNCT05643534 | Ardelyx | Phase 3 | Completed | 2026-08-20Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |